US 8932588
Treatment of cancer involving mutated KRAS or BRAF genes
granted A61KA61K2039/505A61P
Quick answer
US patent 8932588 (Treatment of cancer involving mutated KRAS or BRAF genes) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00